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ABSTRACT
Objective Describe demographical, social and 
psychological correlates of willingness to receive a 
COVID-19 vaccine.
Setting Series of online surveys undertaken between 
March and October 2020.
Participants A total of 25 separate national samples 
(matched to country population by age and sex) in 12 
different countries were recruited through online panel 
providers (n=25 334).
Primary outcome measures Reported willingness to 
receive a COVID-19 vaccination.
Results Reported willingness to receive a vaccine 
varied widely across samples, ranging from 63% to 
88%. Multivariate logistic regression analyses reveal sex 
(female OR=0.59, 95% CI 0.55 to 0.64), trust in medical 
and scientific experts (OR=1.28, 95% CI 1.22 to 1.34) 
and worry about the COVID-19 virus (OR=1.47, 95% 
CI 1.41 to 1.53) as the strongest correlates of stated 
vaccine acceptance considering pooled data and the most 
consistent correlates across countries. In a subset of UK 
samples, we show that these effects are robust after 
controlling for attitudes towards vaccination in general.
Conclusions Our results indicate that the burden of trust 
largely rests on the shoulders of the scientific and medical 
community, with implications for how future COVID-19 
vaccination information should be communicated to 
maximise uptake.
INTRODUCTION
COVID-19 has resulted in over 2.5 million 
deaths globally, illness for millions more and 
unprecedented social and economic disrup-
tion.1 2 Many governments have signalled that 
mass vaccination against the virus is the most 
straightforward—and possibly only—route 
to normality and stability.3 4 While recent 
announcements of effective vaccines5 6 and 
their rollout to certain demographics in some 
countries are promising,7 the wider impact of 
vaccines on preventing the spread of disease 
is dependent on broad uptake within a 
given population. In order to achieve ‘herd 
immunity’, enough people in a population 
must be immune to prevent the spread of a 
disease among non- immune individuals. The 
proportion varies depending on a number of 
factors including how infectious the conta-
gion is, its prevalence in a population and 
the variation in individual susceptibility or 
exposure to infection.8 Estimates for the level 
of immunity required for COVID-19 herd 
immunity have ranged from 50% to 80% 
of the population, acquired through either 
natural infection and recovery or vaccina-
tion.9 10 It must be noted that, while there is 
evidence that currently available vaccines can 
reduce SARS- CoV-2 infections,11 there is only 
limited preliminary evidence that vaccina-
tion can reduce transmission of the virus at 
the time of writing.12 Thus, the net impact of 
vaccination campaigns on the spread of the 
virus remains uncertain until more research 
is conducted.13
Vaccine hesitancy—defined as a delay in 
acceptance or refusal of vaccines despite avail-
ability14—poses a challenge to achieving herd 
immunity. If a sufficient number of people in 
a population reject vaccination—and herd 
Strengths and limitations of this study
 ► To examine predictors of vaccine acceptance, we 
collected data from a large number of participants 
in several different countries and at different time 
points.
 ► We examine a range of demographical, risk and 
trust- related predictors using multivariate models.
 ► Samples were quota matched (age and gender) to 
country population, but not probability sampled.
 ► At the time of the surveys, no COVID-19 vaccine 
was publicly available; thus, stated acceptance is 
hypothetical and may change with provision of more 
information about current vaccines.
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immunity is not achieved—the virus will continue to 
circulate among susceptible individuals, including those 
who are unable to be vaccinated for medical reasons. 
The WHO identified vaccine hesitancy as one of the top 
10 threats to global health in 2019,15 and in the pressing 
context of COVID-19, understanding vaccine hesitancy 
has only grown in importance.16
Public health researchers concerned with uptake of 
vaccination have understandably sought to uncover the 
drivers of vaccine hesitancy. By identifying antecedents 
of vaccine hesitancy, policy makers, public health offi-
cials and professional communicators can target inter-
ventions to increase uptake of vaccines and ultimately 
reduce the burden of disease in a population.4 However, 
strategies developed for campaigns targeting diseases 
with well- established vaccines (eg, measles, mumps and 
rubella (MMR) and pertussis) may not fully translate to a 
pandemic context where there is greater uncertainty and 
less information available and where institutional trust 
plays a greater role—as was noted in the wake of the 2009 
H1N1 influenza pandemic.17
Recent evidence shows that acceptance of a COVID-19 
vaccine is far from universal in many countries. Lazarus 
et al18 conducted a series of surveys across 19 countries 
in June 2020, asking respondents how much they agreed 
with the following statement: ‘If a COVID-19 vaccine is 
proven safe and effective and is available, I will take it’. 
The proportion of respondents who agreed ranged from 
88.6% (China) to 55.8% (Russia). Examining possible 
predictors of vaccine acceptance, the authors report that 
men, older people and those who express greater trust in 
the government were more likely to express willingness 
to receive a vaccine. The role of trust (in science, the 
government or the medical system) is a recurring theme 
in many other recent studies, which have examined 
COVID-19 vaccine hesitancy in individual countries.19–27 
For example, Palamenghi et al24 report that across two 
large random samples of the Italian population, trust in 
science was positively correlated (r=0.37) with willing-
ness to receive a COVID-19 vaccine. Frank and Arim20 
report that Canadians who are more trusting of local and 
national government bodies are more likely to express 
intentions to receive a vaccine if available, as are those 
who report high general social trust (ie, believing that 
‘most people can be trusted’).
Such results align with pre- COVID studies that have 
highlighted the role of trust in vaccination intentions and 
attitudes.17 28 29 However, we note that recent studies exam-
ining COVID-19 vaccine intentions have typically only 
examined trust in one entity (eg, government or hospi-
tals); research to date has not considered the possible 
overlap between trust in the government, trust in science 
and medicine and general social trust.30–32 There is also 
a question over the extent to which vaccine acceptance 
is linked to mistrust in experts and authorities regarding 
COVID-19 in particular or a more general lack of trust in 
these actors. In order to target communications specifi-
cally designed to satisfy the information needs of those 
who distrust official authorities, it is important to identify 
the precise agents that they distrust (and, ideally, why).
Beyond trust, the perceived threat or risk posed by a 
given disease has also been shown to predict vaccination 
attitudes. Models of health behaviour, such as the health 
belief model33 and protection motivation theory34, place 
the perceived risk or severity of a disease as a key driver 
of vaccination intentions (and other preventative health 
behaviours).17 35 Recent surveys in the USA, Malaysia and 
Israel have shown that perceived risk and worry regarding 
the COVID-19 virus are associated with vaccine accep-
tance.36–38 Other factors, such as the perceived benefits 
and costs as well as efficacy of protective behaviours, are 
also outlined in models of health behaviour as predictors 
of engagement in a given health behaviour. However, 
until recently, little information about the possible costs, 
distribution and efficacy of a COVID-19 vaccine was avail-
able, meaning that the public has not generally been able 
to assess the potential benefits of a vaccine outside of a 
purely hypothetical arena (although experimental work 
has examined the influence of these factors on willing-
ness to receive a vaccine39).
There are also increasing concerns about the politici-
sation of science and about politics becoming entangled 
with vaccine beliefs and attitudes specifically, particularly 
in the context of a pandemic where central government 
structures are deeply involved in all stages of the public 
health response.17 40 Prior research41 has shown that the 
rhetoric adopted by political elites on social media can 
fuel antivaccination attitudes among their followers and 
that ideologies can help explain antivaccination atti-
tudes.37 42
In the current study, we present a more comprehen-
sive international analysis of the role of key social, polit-
ical and psychological correlates of COVID-19 vaccine 
acceptance across 12 countries, with multiple national 
surveys in some countries (total n=25 334; see table 1). All 
samples were recruited via online panel providers using 
quotas to ensure samples were matched to the general 
population in terms of age and gender (with the excep-
tion of France; see Methods section). Unlike previous 
studies, we examine reported trust in a range of actors, 
both in general and specifically relating to the COVID-19 
pandemic. We also include several demographical factors 
(including political orientation); numeracy (known to 
play a role in risk perceptions43 and vaccine attitudes in 
particular44); affective (worry) and cognitive (perceived 
likelihood of infection) aspects of perceived COVID-19 
risk45; broad measures of perceived efficacy; and, in a 
subset of samples, general attitudes towards vaccines.
METHODS
Participants and procedure
Between March and October 2020, we fielded 25 sepa-
rate surveys across 12 countries. The majority of samples 
were recruited through an ISO- certified international 
survey company Respondi ( respondi. com). Our initial 
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US and UK samples were recruited via Prolific ( prolific. 
ac). Although some later samples from these countries 
were recruited via Respondi, we continued to also recruit 
Prolific samples to allow comparisons with our earliest 
data points in the pandemic. As we did not have matching 
Prolific and Respondi samples at each time point and 
results differed slightly between these providers, we 
report these samples separately for transparency. Recruit-
ment was managed by these external providers, and exact 
response rates were not provided. However, Respondi 
provided a broad estimate of a 30% response rate across 
surveys (personal communication; Respondi, 2021). Non- 
response bias was mitigated by quota- based sampling, 
which ensured all samples were representative of each 
country’s population in terms of age and gender (using 
interlocking quotas based on national census data) and, 
in Prolific samples, ethnicity.46 We also control for socio-
demographic factors such as education level and political 
orientation in analyses below. Participants who had previ-
ously completed a survey were prevented from completing 
further surveys, so all our samples represent different 
individuals. Participants who did not finish the survey 
were excluded. Demographical details for each sample 
are shown in table 1. For completeness, we include several 
samples in which vaccine acceptance was measured, but 
the survey did not include all the independent variables 
used in the models presented below. Surveys that did not 
include all these variables are marked with a ‘*’ in table 1.
All participants were directed via a study link to the 
Qualtrics platform and provided informed consent 
before completing the survey. This study was approved by 
the University of Cambridge psychology research ethics 
committee (PRE.2020.034).
It is important to note that the surveys were conducted 
at various time points as the pandemic unfolded in 
each country. Table 1 also reports the total number of 
COVID-19 deaths for each country at each survey time 
point and the number of reported cases in the week prior 
to the survey (with the caveat that reporting practices 
vary between countries). We also provide the Stringency 
Index measure generated by the COVID-19 Govern-
ment Response Tracker,47 which is a 0–100 index based 
on various restrictions put in place by governments to 
control the pandemic (eg, closing schools and ‘shelter in 
place’ requirements). External data were sourced from 
the COVID-19 Government Response Tracker47 and Ali 
et al.48
The information about potential vaccines also changed 
over the data collection period. In February 2020, the 
first major vaccine candidates, the Moderna and Oxford–
AstraZeneca vaccines, were announced.49 50 In mid-2020, 
the launches of phase III trials for several vaccines were 
announced: Moderna and Pfizer–BioNTech in July51 and 
AstraZeneca in August.52 Results of phase III clinical trials 
and estimates of efficacy were not announced during the 
data collection period (ending in October 2020). No 
vaccines were approved for use by local regulators at the 
time(s) the surveys were conducted in each country.
Materials
Participants reported their age and gender, level of 
education (ranging from no formal education above age 16 
to PhD) and political orientation (very liberal/left wing to 
very conservative/right wing). Numeracy was measured as 
a combined index of the 2–3- item adaptive form of the 
Berlin Numeracy Test53 and an additional risk literacy 
item from Lipkus et al.54
Participants completed a widely used measure of 
general social trust (generally speaking, would you say most 
people can be trusted or that you can't be too careful in dealing 
with people?)55 and a separate measure of prosociality (to 
what extent do you think it’s important to do things for the 
benefit of others and society even if they have some costs to 
you personally?). Trust in experts and trust in the govern-
ment were each measured as the combined average 
of reported trust in three targets (experts: scientists, 
medical doctors and nurses and scientific knowledge 
(Cronbach’s αs: 0.77–0.86); government: politicians, 
current government and civil servants (Cronbach’s αs: 
0.73–0.90); and all from cannot be trusted at all to can 
be trusted a lot). We also asked participants to report 
their trust in several actors with specific regard to the 
COVID-19 pandemic. Participants reported the extent 
to which they trust politicians in their country to ‘deal 
effectively with the pandemic’ and how much they 
separately trusted the country’s national scientific and 
medical advisors, independent experts not connected 
with the government and the WHO to ‘know the best 
measures to take in the face of the pandemic’ (all from 
not at all to very much). Personal and government effi-
cacy were captured by items asking participants the 
extent to which they felt that, respectively, their own 
actions and the actions of their country ‘to limit the 
spread of coronavirus can make a difference’ (not at 
all to very much). Perceived likelihood of infection was 
measured as an index of three related items (example: I 
will probably get sick with the coronavirus/COVID-19; Cron-
bach’s αs: 0.71–0.89). Participants also reported their 
level of worry about the virus (from not at all worried to 
very worried). In a subset of UK samples, we also asked 
participants about their general attitude towards vacci-
nation, using two items from Lewandowsky et al’s42 scale 
(example: I believe that vaccines are a safe and reliable way 
to help avert the spread of preventable diseases (Pearson's rs: 
0.83–0.87).
Participants’ vaccine acceptance was measured with 
the following question: ‘If a vaccine were to be avail-
able for the coronavirus/COVID-19 now, would you 
get vaccinated yourself?’ (yes/no). Participants were 
also asked, ‘If a vaccine were to be available for the 
coronavirus/COVID-19 now: Would you recommend 
vulnerable friends/family to get vaccinated?’ (yes/no). 
Full- item wording for all measures can be found in 
online supplemental table S1.
Surveys were translated from English to other languages 
by native speakers fluent in English.
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Analysis
To examine the correlates of vaccine acceptance, we 
fitted a multivariate logistic regression model to the data 
from each survey. To allow for descriptive comparisons 
between countries and across time, we report model 
results separately for each country, time point and (in 
the UK) panel provider. We also report results from the 
model fitted to the pooled data from all surveys and a 
supplementary multilevel model adjusting for survey- level 
variables (total number of cases and days since the first 
case in the country at time of survey). All analyses were 
conducted in R (V.4.0.5).
RESULTS
Figure 1 shows the percentage of participants in each 
survey who responded that they would be willing to 
be vaccinated if a COVID-19 vaccine was available or 
would recommend a vaccine to vulnerable others, given 
the options of ‘yes’ or ‘no’ (based on respondents who 
answered the question). In the Italy sample, a number of 
participants were not presented with these items due to a 
technical error (n=80, 11%). In the remaining samples, 
the average proportion of missing responses for vaccine 
intention and recommendation items was 1% (see online 
supplemental tables S2 and S3 for description of missing 
data and the age and gender distribution of those partic-
ipants who answered the vaccine acceptance item). We 
acknowledge that in some cases, estimates of vaccine 
acceptance may not be based on samples exactly matched 
to a country’s population age and gender distribution 
due to this missing data, but note that age and gender are 
controlled for in the models below. Across all samples, 
the percentage of respondents who stated they were 
willing to receive a vaccine ranged from 62.6% (Sweden, 
April) to 88.1% (Mexico, March), while the percentage 
of those who said they would recommend a vaccine 
to vulnerable others ranged from 67.5% (the USA, 
September) to 91.7% (the UK, March). Descriptively, 
in every single sample, the proportion of respondents 
stating a willingness to receive a vaccine was lower than 
the proportion who would recommend it to vulnerable 
others (Mdiff=−5.79%, SD=3.00). We also note a trend of 
decreasing stated acceptance over time: in nearly all coun-
tries with multiple samples, vaccine acceptance in any 
given survey was lower than previous surveys of the same 
population. For example, between March and May 2020, 
stated vaccine acceptance among respondents in Mexico 
dropped from 88.1% to 73.9% (a χ2 test of independence 
indicated that this difference was statistically significant, 
χ2=42.44, p<0.001) In the USA, stated vaccine acceptance 
(among participants recruited through online panel 
provider Respondi) fell more than 12 percentage points, 
from 74.7% to 62.6%, between May and September 2020 
(χ2=25.89, p<0.001).
We fitted a multivariate logistic regression model 
to data from each sample to identify the correlates of 
COVID-19 vaccine intentions. Independent variables 
included demographical variables; an objective measure 
of numeracy and political ideology; general social trust; 
prosociality (perceived importance of doing ‘things 
for the benefit of others and society’ even at personal 
cost); general trust in medical and scientific experts; 
general trust in the government; specific trust in politi-
cians to manage the pandemic; specific trust in (sepa-
rately) national science advisors, independent scientists 
and the WHO to ‘know the best measures to take in the 
face of the pandemic’; the perceived efficacy of their 
own and their country’s actions to limit the spread of 
the virus; perceived likelihood of infection; and worry 
about COVID-19 (for details on measures, see Methods 
section and online supplemental table S1; descriptive 
statistics are reported in online supplemental table S4 
and bivariate correlations in online supplemental figure 
S1). Continuous measures (ie, all except gender) were 
scaled and mean centred prior to analysis. Only complete 
observations were included. Multicollinearity analyses 
indicated no issues arising from correlated predictors (all 
variance inflation factor values <4). To facilitate the inter-
pretation of results, we present ORs in a heat map format 
in figure 2. Full model results including CIs can be found 
in online supplemental table S5. Results of models inves-
tigating correlates of willingness to recommend a vaccine 
to vulnerable others are also presented in supplementary 
materials (online supplemental figure S2, table S6). We 
fitted an additional multilevel model to the pooled data, 
adjusting for country, month, days since first case, level 
of government intervention, total reported deaths and 
number of cases reported in each country at each time 
Figure 1 COVID-19 vaccine acceptance across countries 
and time. Percentage of respondents who stated they were 
willing to receive or recommend a COVID-19 vaccine across 
surveys. UK and US samples using different panel providers 
are reported separately.
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point (online supplemental table S7). Fixed effects were 
essentially unchanged from those reported in the simpler 
pooled model. Due to the low number of groups, esti-
mates of random effects were unreliable.56
Considering the most consistent correlates of stated 
vaccine acceptance across samples, we find that in most 
samples, individuals who report a higher level of general 
trust in experts (ORpooled=1.28, 95% CI 1.22 to 1.34) or 
who are more worried about the virus (ORpooled=1.47, 
95% CI 1.41 to 1.53) are more likely to say that they 
would accept a vaccine. In Germany, Spain, Mexico, 
Sweden (March only) and nearly all UK samples, women 
are generally less likely to say that they would accept a 
COVID-19 vaccine if available (ORpooled=0.59, 95% CI 0.55 
to 0.64) (UK data were over- represented in our pooled 
sample). As a robustness check, we also fitted the model 
to the pooled sample with UK data removed and report 
that the effects of gender, trust in experts and worry 
remain significant (ps <0.001; see online supplemental 
table S5). We also note that measures of efficacy, both 
at the personal (ORpooled=1.00, 95% CI 0.96 to 1.05) and 
country level (ORpooled=1.01, 95% CI 0.96 to 1.08), were 
not significantly associated with reported vaccine accep-
tance in most samples.
Our results reveal a great deal of heterogeneity in the 
relevance of correlates across countries but also across 
time in countries where we conducted multiple surveys. 
For example, in the USA, only a few consistent associa-
tions emerged. Most notably, political conservatism was 
associated with a lower likelihood to accept a COVID-19 
vaccine in March (ORUSA—Mar= 0.73, 95% CI 0.57 to 0.93; 
ORUSA—May= 0.77, 95% CI 0.58 to 1.01), whereas trust in 
experts (ORUSA—Mar= 1.53, 95% CI 1.16 to 2.03; ORUSA—May= 
1.36, 95% CI 1.02 to 1.82) and personal worry about the 
virus (ORUSA—Mar= 1.47, 95% CI 1.17 to 1.87; ORUSA—May= 
1.27, 95% CI 0.99 to 1.64) were associated with increased 
vaccination intentions. In contrast, in the UK, additional 
factors such as the role of age, gender and prosociality 
played a significant role. There was also variation over 
time. For example, although political ideology was not 
a significant correlate in the UK in May or July 2020, 
conservatism was associated with lower vaccination inten-
tions from September 2020 onwards (ORs 0.85–0.88), 
which may be related to increased polarisation. To illus-
trate the increasing strength of the association between 
political ideology and vaccine acceptance over time in 
the UK, in figure 3, we plot the predicted likelihood of 
reported vaccine acceptance across the political spectrum 
(holding all other variables constant).
In the UK, we also report a different pattern of effects 
when comparing between samples collected via different 
providers, even where these were collected on the same 
day (in May, July and September), matched on age and 
gender and controlling for a range of other demograph-
ical variables. This underscores the caution that must 
be applied when studies generalise results from a single 
survey sample (particularly an online survey).
In terms of variance explained, the variables in our 
model explained approximately 10%–30% of the vari-
ance in the likelihood of vaccine acceptance versus 
Figure 2 Correlates of vaccine acceptance. Heat map of ORs in multivariate logistic regression model predicting stated 
vaccine acceptance. Columns represent individual samples, and rows represent independent variables in model. Grey values 
are non- significant (p>0.05). Red shading indicates a lower likelihood of reported vaccine acceptance and blue shading a higher 
likelihood. For space, samples are defined by their two- character ISO country code and a letter denoting participant source (B, 
BVA; D, Dynata; P, Prolific; and R, Respondi). Political orientation data were not collected in the French sample; this sample is 
excluded from pooled data.
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refusal, with the exception of samples recruited in South 
Korea (4%) and Japan (8%).
Accounting for general vaccine attitudes
To examine the extent to which the effects in our model 
can be accounted for by a negative perception of vaccines 
in general, we conducted an additional set of analyses. 
In our three most recent UK surveys, we included a 
two- item measure of general vaccine attitudes (adapted 
from Lewandowsky et al42). A comparison of results from 
models with or without general vaccine attitudes as an 
independent variable is shown as a heat map in figure 4. 
Although attitudes toward vaccination increase the 
explained variance of our model (ΔR2 4%–9%) and reveal 
strong significant effects such that more positive attitudes 
are associated with increased vaccination intentions (ORs 
1.69–2.32; full results in online supplemental table S8), 
the relationships in the original model appear robust 
and are only minimally attenuated when accounting for 
generalised attitudes.
DISCUSSION
Understanding the psychological determinants of vaccine 
acceptance and hesitancy is crucial during a global 
pandemic. Across all countries surveyed, between March 
and September 2020, a substantial proportion of partici-
pants (up to 37% in some countries) said that they would 
not accept a hypothetical COVID-19 vaccine. People were 
slightly more likely to say that they would recommend it 
to vulnerable friends and family members. Considering 
who is more or less likely to report willingness to be 
vaccinated against COVID-19, being a man, expressing 
general trust in those with scientific or medical exper-
tise and worrying about the virus are the most consistent 
correlates of vaccine acceptance across our samples. It 
is important to note that hesitancy about a COVID-19 
vaccine is not purely attributable to people’s attitudes 
to vaccines in general. Although (in the UK, where we 
studied it) negative attitudes towards vaccines in general 
are a significant and important correlate of COVID-19 
vaccine refusal, there are clearly additional factors at play 
in determining public reactions to a COVID-19 vaccine. 
This broadly aligns with other researches indicating that, 
Figure 3 Political ideology and vaccine acceptance in the UK. Predicted likelihood that an individual will accept being 
vaccinated at varying levels of political ideology (1=very liberal/left wing and 7=very conservative/right wing) in UK samples over 
time.
Figure 4 Negative general attitudes towards vaccination 
do not fully account for relationships in the model. Results of 
multivariate logistic regression models investigating reported 
COVID-19 vaccine acceptance in UK samples, excluding (left 
panel) or including (right panel) general vaccine attitudes as 
an independent variable. ORs shown are based on scaled 
variables (other than gender). Grey values are non- significant 
(p>0.05). For space, samples are defined by a letter denoting 
participant source (P, Prolific; R, Respondi).
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for many people, there are concerns specifically around 
the rapid and novel development processes of COVID-19 
vaccines and possible safety issues.36 57 Our multivariate 
analyses show that the bulk of the burden of trust rests 
on science and medicine. This is in line with other recent 
studies specifically examining the association between 
trust in scientists and doctors and COVID-19 vaccine hesi-
tancy.26 27 Accounting for the other factors in our model, 
we find that trust in the government (both generally and 
regarding COVID-19) and general social trust (ie, trust 
in people) are not significantly associated with vaccine 
acceptance in most of our samples. Since the period 
of data collection, more information about COVID-19 
vaccines, including their safety and efficacy, has become 
available. It remains to be seen how this information has 
shifted vaccine intentions. As the public focus has shifted 
from vaccine development to the regulatory approval and 
rollout of vaccines,11 it is possible that trust in the govern-
ment and regulators may play a greater role in individ-
uals’ vaccine decision making. However, further research 
is required to confirm this speculation.
The fact that we saw only a weak link between stated 
vaccine acceptance and our measure of prosociality—
along with the fact that higher numbers of people said 
that they would recommend the vaccine to a vulnerable 
friend or relative than say they would accept it them-
selves—suggests that the prosocial nature of vaccines may 
not be recognised by many people. Recent experimental 
research has shown that emphasising the societal benefits 
of herd immunity (ie, the need for those who do not see 
themselves as personally vulnerable to take the vaccine in 
order to provide protection for those who are) may assist 
uptake.58 However, such strategies depend on vaccines 
preventing transmission of the virus, rather than just symp-
toms. There is now preliminary evidence that this is the 
case for the Moderna and Pfizer–BioNTech vaccines,12 
but further studies are required to confirm these findings.
The greater reluctance from women to say that they 
would take a vaccine is in line with other work focusing 
on acceptance of a potential COVID-19 vaccine18 19 and 
vaccination generally29 but has not been adequately 
explained. Even when general vaccine beliefs are taken 
into account, however, the gender bias remains. Qual-
itative work should focus on investigating this further, 
in order to understand the root of women’s concerns 
about the COVID-19 vaccine. We see very little effect 
of our measures of personal or governmental efficacy, 
but this may be related to the fact that a vaccine against 
COVID-19 was hypothetical at the time of the surveys and 
our measures did not directly ask about vaccination.
Another important finding highlighted by our 
repeated samples is that vaccine acceptance appears to 
be politicised in the USA and is becoming so in the UK. 
Our US results agree with previous US research focusing 
on COVID-19 vaccine acceptance,39 59 which noted that 
political conservatives are less accepting of potential 
COVID-19 vaccines. Our UK results align with those 
of Maher et al, who, through network analysis, show a 
pattern of attitudinal alignment over time in a small UK 
sample, resulting in the emergence of a politically conser-
vative faction expressing less trust in scientists, doctors 
and vaccines.21 Although international research has 
suggested that political conservatism is correlated with 
antivaccination attitudes globally,40 we did not find that 
ideology was associated with vaccine acceptance outside 
of the USA and the UK. However, most other countries 
were only surveyed in earlier stages of the pandemic (ie, 
prior to May 2020), and we can therefore not say whether 
they might have followed a similar pattern to the UK as 
time went on.
It is possible that misinformation susceptibility60 61 and 
conspiracy thinking62 underlie the association between 
ideology and vaccine attitudes to some extent. For 
example, Motta et al63 find that far- right- wing media 
outlets have disproportionally spread misinformation 
during the early stages of the pandemic. Susceptibility 
to misinformation around COVID-19 was also found in 
prior research to be associated with measures of vaccine 
hesitancy.61 There is already a proliferation of conspiracy 
theories focused on specific COVID-19 vaccines.64 65 
It will be important to tackle these proactively through 
‘prebunking’ methods to inoculate against misinforma-
tion.66 67
We must note that our surveys did not examine several 
sociodemographic factors that could explain additional 
variance in vaccination intentions; ethnic minority status, 
socioeconomic status and underlying health conditions 
have all been shown to be associated with COVID-19 
vaccine hesitancy in some contexts.68 69 Future research 
should examine how these factors relate to vaccine confi-
dence and intentions as vaccine campaigns progress.
Finally, we acknowledge that the heterogeneity in our 
results across time and countries highlights the role that 
(unmeasured) contextual, country- specific factors play in 
informing individuals’ vaccination attitudes. As noted by 
the WHO Strategic Advisory Group of Experts on Immu-
nization working group on vaccine hesitancy, individual 
factors such as trust and risk perception intersect with 
contextual influences such as culture, media environ-
ments and information from local leaders.14 Our samples 
were not truly representative of the general population 
in each country: although they were quota- balanced 
on gender and age, the population that responds to an 
online questionnaire will differ from the general popu-
lation on several significant characteristics. However, the 
rank ordering of countries on vaccine acceptance in our 
study is similar to that of Lazarus et al,18 which were based 
on a random stratified sampling approach using several 
online panel providers. This gives us some confidence in 
the generalisability of our results, and the fact that our 
samples were generally larger and included more trust- 
focused questions makes them useful for exploring these 
important correlates of vaccine attitudes.
In terms of practical considerations, our finding that 
trust in scientific and medical institutions is one of the 
strongest correlates of vaccine acceptance highlights the 
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need to work proactively with others from outside of this 
sphere, such as community and religious leaders,70 to 
open a two- way conversation with those who distrust the 
scientific and medical establishment. Due consideration 
must also be given to the accessibility,71 format72 73 and 
transparency74 75 of information provided to the public. 
Future research should continue to evaluate how to most 
effectively communicate evidence about vaccination76 
and should seek to more deeply understand the concerns 
and needs of those who express hesitancy regarding 
COVID-19 vaccination. As Bhopal,77 commenting on 
potential COVID-19 mass vaccination efforts, writes, 
‘open, honest, factual and sensitively conducted public 
dialogue is now urgent’.
CONCLUSIONS
Countries around the world face a major evidence 
communication challenge when it comes to the 
COVID-19 vaccines that are becoming available. In order 
to reach a large enough proportion of the population 
in each country to achieve herd immunity, it is vital to 
increase the number of people who are willing to take 
a vaccine. To achieve this, non- pharmaceutical interven-
tions will need to be deployed,78 such as communicating 
trustworthy information about the vaccines via credible 
sources. In the current research, we have demonstrated 
across 12 national samples that people’s level of worry 
about COVID-19 and their trust in experts and medical 
and scientific institutions are key determinants of poten-
tial vaccine acceptance. Future research should confirm 
these findings in experimental settings. We recommend 
that empirical studies should continue to be carried out 
alongside qualitative work with different communities 
to get a rounded understanding of people’s concerns 
and misunderstandings. Only by knowing these can we 
adequately address them and provide people with the 
information they need to make a decision that will affect 
not just their own health, but that of their community as 
well.
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